Referenser
1. Avamys produktresumé 2009/12.
2. Canonica GW. A survey of the burden of allergic rhinitis in Europe. Allergy 2007;62(suppl 85):17–25.
3. Fokkens WJ, Jogi R, Reinartz S et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007; 62: 1078-1084.
4. Kaiser HB, Naclerio RM, Given J et al. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 119(6): 1430-1437.
5. Martin BG, Ratner PH, Hampel FC et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007; 28(2): 216-225.
6. Ratner P, Andrews C, van Bavel J et al. Once-daily fluticasone furoate* nasal spray (FF) effectively treats ocular symptoms of seasonal allergic rhinitis (SAR) caused by mountain cedar pollen.*USAN approved name. J Allergy Clin Immunol 2007; 119(Supp 1): S231.
7. Maspero JF, Walters RD, Wei W et al. The efficacy of fluticasone furoate on 7 individual nasal and ocular symptoms of seasonal allergic rhinitis. Abstract 524, World Allergy Congress, Buenos Aires, December 2009.
8. Gueron B et al. Quality of life and work productivity in Allergic Rhinitis patients suffering from both nasal and ocular symptoms – an observational, cross sectional study in 4 countries in Europ. Poster presenterad på XXVIII EAACI Congress, Warsaw, 6-10 Juni 2009.
9. Keith PK, Scadding GK. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr Med Res Opin 2009; 25:2021-41 och Curr Med Res Opin 2010; 26:177
10. van Bavel J, Toler T, Ellsworth A et al. Once-daily fluticasone furoate* nasal spray (FFNS) improves quality of life (QoL) in subjects with seasonal allergic rhinitis (SAR) during the mountain cedar pollen season.*USAN approved name. J Allergy Clin Immunol 2007;119(Supp 1): S230.
11. Vasar M, Houle P, Douglass J et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 2008; 29: 313-321.
12. Salter M, Biggadike K, Matthews JL et al. Pharmacological properties of the enhanced- affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007; 293: 660-667.
13. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007;4(6):689–701.
14. Berger W, Godfrey JW, Grant AC et al. Fluticasone furoate (FF) nasal spray - development of a next-generation delivery system for allergic rhinitis. J Allergy Clin Immunol 2007; 119(Suppl 1): S231.
15. Godfrey JW, Grant AC, Slater AL. Fluticasone furoate (FF) nasal spray – ergonomic considerations for a next generation delivery system. J Allergy Clin Immunol 2007; 119(Suppl 1): S230.
16. Veramyst (fluticasone furoate) label information; http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022051s002lbl.pdf Accessed 22 april 2010.
17. Patel D, Ratner P, Clements D et al. Lack of effect on adult and adolescent HPA axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol 2008; 100: 490-496.
18. Nathan R, Berger W, Yang W et al. Once-daily fluticasone furoate nasal spray relieves nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008; 100: 497-505.
19. Rosenblut A, Bardin PG, Muller B et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071–1077.
20. Allen A, Down G, Newland A et al. Absolute bioavailability of fluticasone furoate nasal spray in healthy subjects. Clin Ther 2007; 29(7): 1415-1420.
21. Mandl M, Nolop K, Lutsky B. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997; 79: 370-378.
22. Drouin M. Yang W, Bertrand B et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996; 77: 153-160.
23. Koepke JW, Beaucher WN, Kobayashi RH et al. Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Asthma Proc 1997; 18(1): 33-7.
24. Baroody FM, Shenaq D, deTineo M, et al. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009;123:1342-8
25. Valotis A, Ho gger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 2007;8:54